- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07949045
Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology (EPIDOCAVILH)
Pilot Study for the Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology
In France, the number of new cancer cases across all cancer types was estimated at 382,000 in 2018. The impact of pain on a patient's quality of life is profound, with physical consequences (insomnia, fatigue, loss of appetite), psychological effects (anxiety, depression, demoralization, attention deficit, memory disorders), and social repercussions.
Acute pain induced by cancer, when poorly managed, can lead to the development of secondary chronic pain syndrome. The French National Authority for Health (Haute Autorité de Santé, HAS) deplores the late referral of patients with chronic pain, which complicates treatment and limits opportunities for improvement. Cancer-related pain has become a chronic condition in 50% of patients, leading to anxiety-depressive syndromes as well as social consequences such as social isolation or difficulty returning to professional activity.
In France, the 2017 White Paper by the SFETD (French Society for the Study and Treatment of Pain) notes that, despite three successive Cancer Plans integrating supportive care into the comprehensive management of cancer patients, one in three patients does not receive analgesic treatment appropriate to the intensity of their pain. To prevent chronic pain, the HAS recently recommended early assessment of acute pain (within less than a week) with a high-quality city-hospital organization.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This study proposes a systematic care pathway for the evaluation and treatment of pain in patients experiencing pain symptoms at the time of cancer diagnosis or relapse. A multidimensional pain assessment consultation will be conducted within 48 hours, along with the implementation of appropriate treatment. The patient will receive therapeutic education for self-assessment of pain, enabling the general practitioner to adjust analgesic treatments on an outpatient basis. The relevance of this pathway lies in the systematic assessment of pain and close collaboration between the general practitioner and the hospital, coordinated by a pain specialist. The general practitioner, who has an in-depth knowledge of the patient, should remain the primary coordinator of the patient's health pathway.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: STEPHANIE NOEL
- Numero di telefono: 0033549443083
- Email: stephanie.noel@chu-poitiers.fr
Backup dei contatti dello studio
- Nome: MAUD BRECHET
- Numero di telefono: 0033549029991
- Email: MAUD.BRECHET@chu-poitiers.fr
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patient ≥ 18 years old.
- Consultation for treatment initiation (first-line or relapse) for gynecological, digestive, urological, or hematological cancer.
- Patient experiencing pain related to a cancer pathology (pain numerical rating scale ≥ 1) for less than 3 months.
- Patient receiving outpatient cancer treatment at the Châtellerault site of Poitiers University Hospital.
- Patient declaring having a general practitioner.
- Patient's general practitioner agreeing to participate in the study.
- Patient covered by the French social Security system or through a third party.
Non-Inclusion Criteria:
- Patient already receiving care for this pain from the reference pain center or supportive care team.
- Patient unable to understand, write, or speak French.
- Patient diagnosed with uncontrolled psychiatric disorders.
- Patient with chronic pain unrelated to cancer.
- Pain related to therapeutic procedures.
- Patient residing in a medicalized facility.
- Patient under enhanced protection, including: minors, pregnant or breastfeeding women, individuals deprived of liberty by judicial or administrative decision, individuals staying in a healthcare or social institution, adults under legal protection (guardianship, curatorship, or subordination), patients in emergency situations.
- Patient with a significant impairment of general condition (ECOG-PS > 2, Eastern Cooperative Oncology Group Performance Status) or cognitive disorders.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Early management of acute pain
Day 0: Multidimensional pain assessment (MPA) consultation conducted by a qualified paramedical professional (QPP) within 48 hours following the oncology consultation. Multidimensional pain will be evaluated using the Brief Pain Inventory-Short Form (BPI-SF). The QPP transfers a report of this assessment to the general practitioner of the patient. Appropriate treatment of pain is implemented by the QPP. Day 2: Consultation with the general practitioner. Based on the report send by the QPP at day 0 and with the self-administration of the BPI-SF fulfilled by the patient at day 2, the general practitioner adjusts pain-relieving treatments if necessary. Day 7: MPA consultation conducted by the QPP who transfers a report of the BPI-SF assessment to the general practitioner. If the patient reports pain symptoms at day 7, then consultation with the general practitioner and MPA consultation are repeated ever week until resolution of pain symptoms. |
Brief Pain Inventory-Short Form is performed twice every week (for the multidimensional pain assessment consultation and for the general practitioner consultation) until resolution of the pain symptoms or up to day 28 (end of the study). |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of eligible patients that provide a consent to participate
Lasso di tempo: 1 day
|
Patient's acceptability will be assessed if ≥ 80% of the eligible patients provide a signed consent. |
1 day
|
|
Proportion of general pactitioner that confirmed their participation
Lasso di tempo: 2 days
|
General practitioner's acceptability will be assessed if ≥80% of the practitioners related to the eligible patients confirmed their participation. |
2 days
|
|
Proportion of consultations with the general practitioner performed
Lasso di tempo: 28 days
|
Completion of consultations with the general practitioner will be assessed if ≥ 80% of the consultations with the general practitioner recommended by the pathway are completed. |
28 days
|
|
Proportion of consultations at the hospital performed
Lasso di tempo: 28 days
|
Completion of consultations at the hospital will be assessed if ≥ 80% of the consultations at the hospital recommended by the pathway are completed. |
28 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in pain severity after 28 days
Lasso di tempo: 28 days
|
Pain severity is assessed using the dimension "pain severity" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain severity is defined as the difference of the two scores assessed at day 0 and at day 28. Pain severity score ranges from 0 (no pain) to 10 (severe pain). |
28 days
|
|
Change in pain interference after 28 days
Lasso di tempo: 28 days
|
Pain interference is assessed using the dimension "pain interference" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain interference is defined as the difference of the two scores assessed at day 0 and at day 28. Pain interference score ranges from 0 (no pain) to 10 (severe pain). |
28 days
|
|
Change in quality of life after 28 days
Lasso di tempo: 28 days
|
Quality of life is assessed using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer, Quality of Life Core Questionnaire). Change in quality of life is defined as the difference of the global quality of life scores assessed at day 0 and at day 28. Quality of life score ranges from 0 (worst quality of life) to 100 (best quality of life). |
28 days
|
|
Proportion of patients requiring a specific pain management
Lasso di tempo: 28 days
|
Specific pain management includes: hospitalization due to the pain, referral to a pain management center, or referral to a mobile palliative care team. |
28 days
|
|
Global satisfaction of the patients
Lasso di tempo: 28 days
|
Satisfaction of the patient will be assessed using a 5-point Likert scale (0 anchored with "not satisfied at all" and 4 anchored with "very satisfied") |
28 days
|
|
Proportion of patients with a modified prescription by the general practitioner for analgesics treatments
Lasso di tempo: 28 days
|
The proportion of patients with a new analgesic treatment added or with a dose escalation or a dose reduction or a therapeutic switch |
28 days
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Manifestazioni neurologiche
- Malattie del sistema nervoso
- Neoplasie urogenitali
- Neoplasie per sede
- Malattie urogenitali maschili
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Manifestazioni neurocomportamentali
- Disturbi percettivi
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Neoplasie
- Neoplasie gastrointestinali
- Neoplasie urologiche
- Agnosi
- Qualità, accesso e valutazione dell'assistenza sanitaria
- Tecniche investigative
- Metodi epidemiologici
- Terapie
- Raccolta dei dati
- Meccanismi di valutazione dell'assistenza sanitaria
- Qualità dell'assistenza sanitaria
- Sanità pubblica
- Ambiente e salute pubblica
- Controllo del comportamento
- Immobilizzazione
- Sondaggi e questionari
- Moderazione, fisico
Altri numeri di identificazione dello studio
- EPIDOCAVILH
- 2026-A01683-48 (Altro identificatore: French Ethics Committee Number (ID-RCB))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .